Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Hls Therapeutics Inc (HLS.TO)

Hls Therapeutics Inc (HLS.TO)
3.97 x 2100 4.00 x 400
Post-market by (Cboe BZX)
4.00 +0.04 (+1.01%) 03/14/25 [TSX]
3.97 x 2100 4.00 x 400
Post-market 4.00 unch (unch) 15:59 ET
Quote Overview for Fri, Mar 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.95
Day High
4.14
Open 4.14
Previous Close 3.96 3.96
Volume 9,900 9,900
Avg Vol 6,861 6,861
Stochastic %K 18.92% 18.92%
Weighted Alpha +5.37 +5.37
5-Day Change -0.04 (-0.99%) -0.04 (-0.99%)
52-Week Range 3.00 - 5.48 3.00 - 5.48
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 125,900
  • Shares Outstanding, K 31,793
  • Annual Sales, $ 63,074 K
  • Annual Income, $ -27,531 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.81
  • Price/Sales 1.54
  • Price/Cash Flow 10.91
  • Price/Book 1.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +2.04%
on 03/13/25
Period Open: 4.20
4.29 -6.76%
on 03/03/25
-0.20 (-4.76%)
since 02/14/25
3-Month
3.35 +19.40%
on 12/17/24
Period Open: 3.64
4.31 -7.19%
on 01/21/25
+0.36 (+9.89%)
since 12/13/24
52-Week
3.00 +33.33%
on 10/25/24
Period Open: 3.99
5.48 -27.01%
on 04/08/24
+0.01 (+0.25%)
since 03/14/24

Most Recent Stories

More News
HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.00 (+1.01%)
HLS Therapeutics Appoints Christine Elliott to its Board of Directors

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.00 (+1.01%)
HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2024 financial results on Thursday, March...

HLS.TO : 4.00 (+1.01%)
HLS Therapeutics Announces Q3 2024 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.00 (+1.01%)
Stocks in play: HLS Therapeutics Inc.

Will release its Q3 fiscal 2024 financial results on Thursday, November 7. The Company will hold a conference ...

HLS.TO : 4.00 (+1.01%)
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7,...

HLS.TO : 4.00 (+1.01%)
Stocks in play: HLS Therapeutics Inc.

Announces that CEO Craig Millian, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual ...

HLS.TO : 4.00 (+1.01%)
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.00 (+1.01%)
HLS Therapeutics Announces Q2 2024 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.00 (+1.01%)
Stocks in play: HLS Therapeutics Inc.

Announces that it has entered into a Product Listing Agreement with the province of Alberta, for the ...

HLS.TO : 4.00 (+1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product...

See More

Key Turning Points

3rd Resistance Point 4.30
2nd Resistance Point 4.22
1st Resistance Point 4.11
Last Price 4.00
1st Support Level 3.92
2nd Support Level 3.84
3rd Support Level 3.73

See More

52-Week High 5.48
Fibonacci 61.8% 4.53
Fibonacci 50% 4.24
Last Price 4.00
Fibonacci 38.2% 3.95
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals